{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
trimetrexate
to a specific field?
There is one exact (name or code) match for trimetrexate
Status:
US Previously Marketed
Source:
NEUTREXIN by MEDIMMUNE ONCOLOGY
(1993)
Source URL:
First approved in 1993
Source:
NEUTREXIN by MEDIMMUNE ONCOLOGY
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Trimetrexate, a second-generation folate antagonist which was used under brand name NEUTREXIN with concurrent leucovorin administration (leucovorin protection) was indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Nevertheless, this product was discontinued. In present time, trimetrexate with a different combinations is in the phase II of clinical trial for the treatment the following cancer diseases: pancreatic cancer and colorectal cancer (in combination with fluorouracil and leucovorin) and to treat a refractory acute leukemia in combination with leucovorin. Trimetrexate is a competitive inhibitor of dihydrofolate reductase (DHFR) from bacterial, protozoan, and mammalian sources. DHFR catalyzes the reduction of intracellular dihydrofolate to the active coenzyme tetrahydrofolate. Inhibition of DHFR results in the depletion of this coenzyme, leading directly to interference with thymidylate biosynthesis, as well as inhibition of folate-dependent formyltransferases, and indirectly to inhibition of purine biosynthesis. The result is disruption of DNA, RNA, and protein synthesis, with consequent cell death.
Status:
US Previously Marketed
Source:
NEUTREXIN by MEDIMMUNE ONCOLOGY
(1993)
Source URL:
First approved in 1993
Source:
NEUTREXIN by MEDIMMUNE ONCOLOGY
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Trimetrexate, a second-generation folate antagonist which was used under brand name NEUTREXIN with concurrent leucovorin administration (leucovorin protection) was indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Nevertheless, this product was discontinued. In present time, trimetrexate with a different combinations is in the phase II of clinical trial for the treatment the following cancer diseases: pancreatic cancer and colorectal cancer (in combination with fluorouracil and leucovorin) and to treat a refractory acute leukemia in combination with leucovorin. Trimetrexate is a competitive inhibitor of dihydrofolate reductase (DHFR) from bacterial, protozoan, and mammalian sources. DHFR catalyzes the reduction of intracellular dihydrofolate to the active coenzyme tetrahydrofolate. Inhibition of DHFR results in the depletion of this coenzyme, leading directly to interference with thymidylate biosynthesis, as well as inhibition of folate-dependent formyltransferases, and indirectly to inhibition of purine biosynthesis. The result is disruption of DNA, RNA, and protein synthesis, with consequent cell death.
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2014)
Source URL:
First approved in 2014
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Glucuronic acid is a sugar acid that was first identified in urine. It is an intermediate metabolite of the uronic acid pathway. Moreover, glucuronic acid is involved in detoxification of certain drugs and toxins by conjugating with them and forming glucuronides. Glucuronic acid has been found to cause an increase in TLR4-dependent reporter protein expression in a cell line transfected with TLR4 and associated co-signaling molecules, and can cause TLR4-dependent pain in humans.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
D-Galacturonic acid is the main constituent of pectin, a naturally abundant compound. It is the monobasic acid resulting from oxidation of the primary alcohol group of D-galactose to carboxyl. D-Galacturonic acid prepared from pectin can be used to synthesize vitamin C. Native pectin is a mixture of polysaccharides, with the major component a polymer of -D-galacturonic acid. Pectin has numerous other medical and pharmaceutical uses, for example in combination with plant hemicelluloses and lignin, may be useful dietary constituents in preventing coronary heart disease, diverticular disease, ulcerative colitis, and a variety of other Western diseases. Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
